NASDAQ:XAIR

Beyond Air (XAIR) Stock Forecast, Price & News

$2.11

-0.02 (-0.94%)

(As of 12:18 PM ET)

Compare

Today's Range: $2.06
▼
$2.16
50-Day Range: $2.13
▼
$3.66
52-Week Range: $2.06
▼
$8.06

Volume: 127,354 shs
Average Volume: 402,806 shs
Market Capitalization: $66.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.25

Beyond Air MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 475.1% Upside
$12.25 Price Target
Short Interest: Bearish
9.65% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.91
Upright™ Environmental Score
News Sentiment: -0.27
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$915,579 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.88) to ($1.69) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

586th out of 975 stocks

Surgical & Medical Instruments Industry

65th out of 100 stocks

3.5

Analyst's Opinion

Consensus Rating
Beyond Air has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.25, Beyond Air has a forecasted upside of 475.1% from its current price of $2.13.
Amount of Analyst Coverage
Beyond Air has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.65% of the outstanding shares of Beyond Air have been sold short.
Short Interest Ratio / Days to Cover
Beyond Air has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in Beyond Air has recently increased by 9.68%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Beyond Air does not currently pay a dividend.
Dividend Growth
Beyond Air does not have a long track record of dividend growth.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Beyond Air has received a 41.63% net impact score from Upright. Beyond Air seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Medical ventilators", "Clinical research services for the respiratory system", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Beyond Air is -0.91.

1.0

News and Social Media Coverage

News Sentiment
Beyond Air has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Beyond Air this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for XAIR on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Beyond Air to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Beyond Air insiders have bought more of their company's stock than they have sold. Specifically, they have bought $915,579.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
15.58% of the stock of Beyond Air is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 30.60% of the stock of Beyond Air is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Beyond Air are expected to grow in the coming year, from ($1.88) to ($1.69) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Beyond Air is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Beyond Air is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Beyond Air has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Beyond Air (NASDAQ:XAIR) Stock

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

XAIR Price History

30 days | 90 days | 365 days | Advanced Chart

XAIR Stock News Headlines

October 2, 2023 | finance.yahoo.com

Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference

September 27, 2023 | finance.yahoo.com

Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting

October 3, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

September 18, 2023 | finance.yahoo.com

Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder

September 15, 2023 | finance.yahoo.com

Beyond Air Insiders Placed Bullish Bets Worth US$2.3m

September 7, 2023 | finance.yahoo.com

Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region

September 6, 2023 | finance.yahoo.com

Beyond Air® To Participate in the 2023 Cantor Global Healthcare Conference

August 24, 2023 | fool.com

Beyond Air (NASDAQ: XAIR)

October 3, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

August 23, 2023 | benzinga.com

Director of Beyond Air Purchased $243K In Stock

August 11, 2023 | finance.yahoo.com

Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024

August 11, 2023 | finance.yahoo.com

Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024

August 8, 2023 | finance.yahoo.com

Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)

August 1, 2023 | finance.yahoo.com

Beyond Air® To Participate in BTIG’s 2023 Virtual Biotechnology Conference

July 29, 2023 | msn.com

Piper Sandler Initiates Coverage of Beyond Air (XAIR) with Overweight Recommendation

July 28, 2023 | msn.com

Beyond Air ends selloff as Piper Sandler initiates at Overweight

July 24, 2023 | finance.yahoo.com

Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast

July 22, 2023 | msn.com

Truist Securities Maintains Beyond Air (XAIR) Buy Recommendation

July 6, 2023 | msn.com

Beyond Air (XAIR) Price Target Decreased by 7.78% to 16.93

June 22, 2023 | msn.com

Recap: Beyond Air Q4 Earnings

June 22, 2023 | msn.com

Beyond Air, Inc. (XAIR) Reports Q4 Loss, Lags Revenue Estimates

June 22, 2023 | finance.yahoo.com

Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023

June 15, 2023 | finance.yahoo.com

Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem

June 15, 2023 | finance.yahoo.com

Beyond Air® Secures up to $40 Million Debt Financing

June 15, 2023 | msn.com

Beyond Air nears two-month high as BTIG starts at Buy

June 15, 2023 | msn.com

BTIG Initiates Coverage of Beyond Air (XAIR) with Buy Recommendation

June 11, 2023 | finance.yahoo.com

Is Beyond Air (NASDAQ:XAIR) In A Good Position To Invest In Growth?

See More Headlines

Receive XAIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beyond Air and its competitors with MarketBeat's FREE daily newsletter.

XAIR Company Calendar

Last Earnings: 8/10/2023
Today: 10/03/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XAIR
CUSIP: N/A
CIK: 1641631
Web: www.beyondair.net
Phone: (516) 665-8200
Fax: N/A
Employees: 98
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.25
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +475.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.95)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-55,820,000.00
Net Margins: N/A
Pretax Margin: -106,444.07%
Return on Equity: -117.80%
Return on Assets: -79.22%

Debt

Debt-to-Equity Ratio: 0.35
Current Ratio: 5.27
Quick Ratio: 5.16

Sales & Book Value

Annual Sales: $870,000.00
Price / Sales: 77.63
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.40 per share
Price / Book: 1.52

Miscellaneous

Outstanding Shares: 31,710,000
Free Float: 26,770,000
Market Cap: $67.54 million
Optionable: Not Optionable
Beta: -0.28

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Steven Adam Lisi (Age 52)
CEO & Chairman
Comp: $650k

Mr. Amir Avniel (Age 49)
Pres, Chief Bus. Officer & Director
Comp: $400k

Mr. Michael A. Gaul (Age 68)
Chief Operating Officer
Comp: $350k

Mr. Douglas Quinton Larson (Age 52)
CFO, Principal Financial Officer & Principal Accounting Officer

Edward Barger
Head of Investor Relations

Ms. Rebecca Van Doren
Head of Sales

Ms. Kori-Ann Taylor
Head of Marketing

Dr. Andrew R. Colin M.D.
Sr. Medical Director Global Clinical Leadership & Member of Scientific Advisory Board

Mr. Duncan Fatkin
Chief Commercial Officer

Dr. Jeff Myers M.D. (Age 58)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XAIR Stock - Frequently Asked Questions

Should I buy or sell Beyond Air stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beyond Air in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XAIR shares.
View XAIR analyst ratings or view top-rated stocks.
What is Beyond Air's stock price forecast for 2023?: 3 brokerages have issued twelve-month price objectives for Beyond Air's shares. Their XAIR share price forecasts range from $10.00 to $15.00. On average, they predict the company's share price to reach $12.25 in the next twelve months. This suggests a possible upside of 475.1% from the stock's current price.
View analysts price targets for XAIR or view top-rated stocks among Wall Street analysts.
How have XAIR shares performed in 2023?: Beyond Air's stock was trading at $6.49 at the start of the year. Since then, XAIR stock has decreased by 67.2% and is now trading at $2.13.
View the best growth stocks for 2023 here.
When is Beyond Air's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our XAIR earnings forecast.
How were Beyond Air's earnings last quarter?: Beyond Air, Inc. (NASDAQ:XAIR) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.01. The firm earned $0.06 million during the quarter, compared to analysts' expectations of $0.20 million.

What other stocks do shareholders of Beyond Air own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Beyond Air investors own include OPKO Health (OPK), NVIDIA (NVDA), Pfizer (PFE), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Enphase Energy (ENPH), General Motors (GM), Livongo Health (LVGO), Main Street Capital (MAIN) and Ollie's Bargain Outlet (OLLI).
What is Beyond Air's stock symbol?: Beyond Air trades on the NASDAQ under the ticker symbol "XAIR."
How do I buy shares of Beyond Air?: Shares of XAIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Beyond Air's stock price today?: One share of XAIR stock can currently be purchased for approximately $2.13.
How much money does Beyond Air make?: Beyond Air (NASDAQ:XAIR) has a market capitalization of $67.54 million and generates $870,000.00 in revenue each year. The company earns $-55,820,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis.
How can I contact Beyond Air?: Beyond Air's mailing address is 825 EAST GATE BOULEVARD SUITE 320, GARDEN CITY NY, 11530. The official website for the company is www.beyondair.net. The company can be reached via phone at (516) 665-8200.

This page (NASDAQ:XAIR) was last updated on 10/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial